帕博利珠单抗引起中毒性表皮坏死松解症一例  

A case of toxic epidermal necrolysis induced by pembrolizumab

作　　者：贺旭 吕聪聪 毕新岭 HE Xu;LV Cong-cong;BI Xin-ling(Department of Dermatology,the First Affiliated Hospital of Naval Medical University,Shanghai 200433,China)

机构地区：[1]海军军医大学第一附属医院皮肤科,上海200433

出　　处：《实用皮肤病学杂志》2021年第5期309-311,共3页Journal of Practical Dermatology

基　　金：海军军事医学专项(2018JS001);长海医院学科攀峰计划(2019YXK028)。

摘　　要：67岁女性患者,因肺癌应用帕博利珠单抗免疫治疗,3周后皮肤出现多形红斑样损害,后演变为中毒性表皮坏死松解症。组织病理检查显示表皮下水疱,疱内有大量红细胞及淋巴细胞,真皮内混合炎性细胞浸润。诊断:中毒性表皮坏死松解症。予以糖皮质激素和静脉注射人免疫球蛋白联合治疗后,皮损好转,2周后痊愈出院。随访1年,患者皮损无复发。A 67 years old female patient who accepted immunotherapy of pembrolizumab for lung cancer, developed erythema multiforme after the third cycle of the treatment, and the lesions evolved into toxic epidermal necrolysis(TEN) subsequently. Histopathological findings showed subepidermal blisters containing a large number of red blood cells and lymphocytes, and dermal infiltration of mixed inflammatory cells. After being treated with systemic corticosteroid and human immunoglobulin for intravenous injection for half a month, the patient recovered and was discharged. The patient was followed up for 1 year without recurrence.

关 键 词：中毒性表皮坏死松解症 帕博利珠单抗 

分 类 号：R758.25[医药卫生—皮肤病学与性病学] R969.3[医药卫生—临床医学]